WO2000046208A1 - Substituierte pyrazolcarbonsäuren zur bekämpfung von anämien - Google Patents
Substituierte pyrazolcarbonsäuren zur bekämpfung von anämien Download PDFInfo
- Publication number
- WO2000046208A1 WO2000046208A1 PCT/EP2000/000511 EP0000511W WO0046208A1 WO 2000046208 A1 WO2000046208 A1 WO 2000046208A1 EP 0000511 W EP0000511 W EP 0000511W WO 0046208 A1 WO0046208 A1 WO 0046208A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- anemia
- general formula
- carboxylic acids
- substituted
- trifluoromethyl
- Prior art date
Links
- 0 *c(cc1)ccc1C(C=Cc1ccc(C(F)(F)F)cc1)=O Chemical compound *c(cc1)ccc1C(C=Cc1ccc(C(F)(F)F)cc1)=O 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to substituted pyrazole carboxylic acids, processes for their preparation and their use as medicaments, in particular for combating and preventing anemia.
- EPO Erythropoietin
- the EPO levels in the blood are usually low, but if the O 2 content in the blood drops, there is an increase in EPO synthesis and therefore an increase in EPO levels in the blood. As a result, the hematopoiesis is stimulated and the hematocrit increases. This leads to an increase in the O 2 transport capacity in the blood. If the number of erythrocytes is sufficient to transport enough O 2 , the EPO blood concentration drops again.
- a lack of oxygen supply can have a number of causes, e.g. severe blood loss, longer stays at high altitudes, but also
- Rh EPO recombinant human (rh) EPO stimulates erythropoiesis and has therefore been used in the treatment of severe anemias. Rh EPO is also used to increase the body's own blood cells in order to reduce the need for foreign blood transfusions.
- rh EPO Convulsions and cerebral or myocardial infarction due to thrombosis. Furthermore, rh EPO is not available orally and must therefore be administered ip, iv or subcutaneously, which limits its use to the therapy of severe anemia.
- pyrazoles are described in publication WO 97/19039.
- the pyrazole derivatives are synthesized on the solid phase. After cleavage, pyrazole phenyl carboxamides are obtained.
- the present invention relates to substituted pyrazole carboxylic acids of the general formula (I)
- A, D, E and G are the same or different and stand for hydrogen, halogen, trifluoromethyl, hydroxy or for (C, -C 6 ) -alkyl or for (C j -C 6 ) -alkoxy,
- R ' represents hydrogen or (C, -C 6 ) alkyl
- R 2 is naphthyl or a 5- to 6-membered aromatic, optionally benzocondensed heterocycle with up to 3 heteroatoms from the S series,
- N and / or O which are optionally up to 3 times the same or different, are substituted by halogen, (C, -C 6 ) -alkyl, (C r C 6 ) -alkoxy, trifluoromethoxy or trifluoromethyl, or by phenyl is in the 4-position for ring attachment by halogen, (C, - C 6 ) -alkyl, (C r C 6 ) -alkoxy, trifluoromethoxy, trifluoromethyl, nitro, phenyl or dimethylamino or in 2-position for ring attachment by Halogen or in the 2,4-position, 3,4-position or 2,5-position for ring attachment must be substituted by halogen,
- the compounds according to the invention can exist in stereoisomeric forms which either behave like image and mirror image (enantiomers) or do not behave like image and mirror image (diastereomers).
- the invention relates to both the enantiomers and the diastereomers and their respective mixtures.
- the racemic forms can be separated into the stereoisomerically uniform constituents in a known manner.
- Physiologically acceptable salts of the compounds according to the invention can be salts of the substances according to the invention with mineral acids, carboxylic acids or sulfonic acids.
- Salts with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.
- Salts which can be mentioned are salts with customary bases, such as, for example, alkali metal salts (for example sodium or potassium salts), alkaline earth metal salts (for example calcium or magnesium salts) or ammonium salts derived from ammonia or organic Amines such as diethylamine, triethylamine, ethyldiisopropylamine, procaine, dibenzylamine, N-methylmo holin, dihydroabietylamine, 1-ephenamine or methylpiperidine.
- alkali metal salts for example sodium or potassium salts
- alkaline earth metal salts for example calcium or magnesium salts
- ammonium salts derived from ammonia or organic Amines such as diethylamine, triethylamine, ethyldiisopropylamine, procaine, dibenzylamine, N-methylmo holin, dihydroabietylamine, 1-ephenamine or methylpiperidine.
- (C r C 6 ) alkyl represents a straight-chain or branched alkyl radical having 1 to 6 carbon atoms.
- a straight-chain or branched alkyl radical having 1 to 4 carbon atoms is preferred. Examples include: methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-pentyl and n-hexyl.
- a straight-chain or branched alkyl radical having 1 to 3 carbon atoms is particularly preferred.
- (C r C 6 ) alkoxy represents a straight-chain or branched alkoxy radical having 1 to 6 carbon atoms.
- a straight-chain or branched alkoxy radical having 1 to 4 carbon atoms is preferred. Examples include: methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.
- a straight-chain or branched alkoxy radical having 1 to 3 carbon atoms is particularly preferred.
- a 5- to 6-membered aromatic heterocycle with up to 3 heteroatoms from the series S, O and / or N is, for example, pyridyl, pyrimidyl, pyridazinyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl or imidazolyl.
- Pyridyl, pyrimidyl, pyridazinyl, furyl and thienyl are preferred.
- a 5- to 6-membered aromatic benzocondensed heterocycle with up to 3 heteroatoms from the S, O and / or N series represents, for example, benzothiophene, quinoline, indole or benzofuran. Benzothiophene and quinoline are preferred.
- A, D, E and G are the same or different and represent hydrogen, fluorine, chlorine, bromine or trifluoromethyl, R 1 represents hydrogen or methyl,
- R 2 represents optionally benzo-condensed furyl, thienyl or pyridyl, which may be up to 2 times identical or different due to fluorine, chlorine,
- Methyl, methoxy, trifluoromethyl or trifluoromethoxy are substituted, or represents phenyl which is in the 4-position for ring attachment by fluorine, chlorine, methyl, methoxy, trifluoromethoxy, nitro, phenyl, dimethylamino or trifluoromethyl or in the 2-position for ring attachment
- Fluorine or chlorine or in the 3-position for ring attachment must be substituted by fluorine, chlorine or trifluoromethyl or in the 2,4-, 3,4- or 2,5-position for ring attachment by fluorine or chlorine,
- A, D, E and G stand for hydrogen
- R 1 represents methyl
- R 2 stands for thienyl or pyridyl, or stands for phenyl which must be substituted in the 4-position for ring attachment by fluorine, chlorine, methyl, methoxy, trifluoromethyl or trifluoromethoxy,
- R 3 represents a (C, -C 4 ) alkyl radical
- R 1 has the meaning given above
- R 2 has the meaning given above
- R 4 represents a (C r C 4 ) alkyl chain
- R 2 and R 4 have the meaning given above
- R 2 and R 4 have the meaning given above
- Inert organic solvents which do not change under the reaction conditions are suitable as solvents for processes [A] and [B].
- halogenated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, 1, 2-dichloroethane, trichloroethane, tetrachloroethane, 1, 2-dichloroethylene or trichlorethylene, hydrocarbon such as benzene, xylene, toluene, hexane or cyclohexane, dimethylformamide, acetonitrile or alcohol , 2-propanol, tetrahydrofuran or DMSO. It is also possible to use mixtures of the solvents. Tetrahydrofuran, ethanol and DMSO are particularly preferred.
- customary acidic and basic catalysts preferably acidic catalysts (e.g. para-toluenesulfonic acid), are suitable for the reaction of the aldehyde with acetophenone described under [B].
- acidic catalysts e.g. para-toluenesulfonic acid
- the aforementioned reactions generally take place in a temperature range from -78 ° C. to the reflux temperature, preferably from 0 ° C. to the boiling point of the solvent used.
- the aforementioned reactions can be carried out under normal, elevated or reduced pressure (e.g. from 0.5 to 5 bar). Generally one works at normal pressure.
- the saponification of the carboxylic acid esters is carried out by customary methods by treating the esters in inert solvents with customary bases or acids, and in the case of basic saponification, the salts which initially arise can be converted into the free carboxylic acids by treatment with acid.
- the usual inorganic bases are suitable as bases for the saponification. These preferably include alkali hydroxides or alkaline earth hydroxides such as sodium hydroxide, lithium hydroxide, potassium hydroxide or barium hydroxide, or alkali carbonates such as sodium or potassium carbonate or sodium hydrogen carbonate. Sodium hydroxide or lithium hydroxide are particularly preferably used.
- Suitable solvents for the saponification are water or the organic solvents customary for saponification. These preferably include alcohols such as methanol, ethanol, propanol, isopropanol or butanol, or ethers such as tetrahydrofuran or dioxane, or dimethylformamide or dimethyl sulfoxide. Alcohols such as methanol, ethanol, propanol or isopropanol are particularly preferably used.
- the saponification is generally carried out in a temperature range from 0 ° C. to + 100 ° C., preferably from 0 ° C. to + 80 ° C.
- the saponification is generally carried out at normal pressure. But it is also possible to work under negative pressure or overpressure (e.g. from 0.5 to 5 bar).
- the base or the acid is generally used in an amount of 1 to 3 mol, preferably 1 to 2 mol, based on 1 mol of the ester.
- Molar amounts of the reactants are particularly preferably used.
- the compounds of the general formulas (II) and (VII) are known per se or can be prepared by customary methods [cf. Erne, D. et al., Helv. Chim. Acta 62: 994-1006 (1979); Hasegawa, E. et al. J. Org. Chem. 56 (1991), 1631-1635; Watanabe, Kenichi et al., Bull. Chem. Soc. Jpn. 55 (1988) 3208-3211].
- the compounds of the general formula (I) according to the invention have an unforeseeable, valuable spectrum of pharmacological activity and are therefore suitable for the treatment and prophylaxis of diseases. They can preferably be used in pharmaceuticals for the treatment and prophylaxis of anemia, such as, for example, premature anemia, anemia in chronic renal failure, anemia after chemotherapy and anemia in HIV patients, and thus also for the treatment of severe anemia. Even with completely intact endogenous EPO production, additional stimulation of erythropoiesis can be induced by the administration of the compounds according to the invention, which can be used in particular in autologous blood donors.
- the application is preferably oral, transdermal or parenteral. Oral application is very particularly preferred, in which there is a further advantage over the therapy of anemias with rh-EPO known from the prior art.
- the compounds according to the invention act in particular as erythropoietin
- Erythropoietin sensitizers are compounds which are capable of influencing the effect of the EPO present in the body so efficiently that erythropoiesis is increased, in particular that the oxygen supply is improved. Surprisingly, they are orally active, which significantly improves and at the same time simplifies the therapeutic use with the exclusion or reduction of the known side effects.
- the present invention thus also relates to the use of EPO
- Sensitizers for the stimulation of erythropoiesis in particular for the prophylaxis and / or treatment of anemia, preferably severe anemia such as premature anemia, anemia in the case of chronic renal failure, anemia after chemotherapy or anemia in HIV patients.
- EPO sensitizers are also used in the case of completely intact endogenous EPO production. Additional stimulation of erythropoiesis into consideration, which can be used in particular in autologous blood donors.
- the compounds according to the invention thus enable efficient stimulation of erythropoiesis and consequently prophylaxis or therapy of anemia which intervenes before the stage in which the conventional treatment methods with EPO are used. This is because the compounds according to the invention allow an effective influence on the body's own EPO, whereby the direct administration of EPO with the associated disadvantages can be avoided.
- the present invention therefore furthermore relates to medicaments and pharmaceutical compositions which comprise at least one compound of the general
- anemia such as e.g. Premature anemia, anemia with chronic renal failure, anemia after chemotherapy or anemia in HIV patients.
- CD34-positive cells from this cell fraction were analyzed using a commercial purification process (CD34 multisort kit from Miyltenyi) isolated.
- CD34 positive cells (6000-10000 cells / ml) were in stem cell medium (0.9% methyl cellulose, 30% calf serum, 1% albumin (bovine), 100 ⁇ M 2-mercaptoethanol and 2 mM L-glutamine) from StemCell Technologies Inc. resuspended. 10 mU / ml human erythropoietin, 10 ng / ml human IL-3 and 0-10 ⁇ M test substance were added. 500 ⁇ l / well (24-well plates) were cultivated for 14 days at 37 ° C. in 5% CO 2 , 95% air.
- Cultures were diluted with 20 ml 0.9% w / v ⁇ aCl solution, centrifuged for 15 min at 600xg and resuspended in 200 ⁇ l 0.9% w / v ⁇ aCl.
- 50 ⁇ l of the cell suspension were pipetted into 10 ⁇ l benzidine staining solution (20 ⁇ g benzidine in 500 ⁇ l DMSO, 30 ⁇ l H 2 O 2 and 60 ⁇ l conc. Acetic acid). The number of blue cells was counted microscopically.
- mice Normal mice are treated with test substances over several days. The
- Preferred solvents are Solutol / DMSO / sucrose NaCl solution or glycofurol.
- approx. 70 ⁇ l of blood are collected several times by puncturing the retroorbital vein plexus taken with a hematocrit capillary. The samples are centrifuged and the hematocrit determined by manual reading. The primary parameter is the hematocrit increase compared to the baseline value of the treated animals compared to the change in the hematocrit in the placebo control (double standardized value).
- the new active compounds can be converted in a known manner into the customary formulations, such as tablets, dragées, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, non-toxic, pharmaceutically suitable excipients or solvents.
- the therapeutically active compound should in each case be present in a concentration of about 0.5 to 90% by weight of the total mixture, i.e. in amounts sufficient to achieve the dosage range indicated.
- the formulations are prepared, for example, by stretching the active ingredients with solvents and / or carriers, optionally using emulsifiers and / or dispersants, e.g. in the case of the use of water as a diluent, organic solvents can optionally be used as auxiliary solvents.
- the application is carried out in the usual way, preferably orally, transdermally or parenterally, in particular perlingually or intravenously.
- Type of its formulation and the time or interval at which the sales submission takes place In some cases it may be sufficient to make do with less than the above-mentioned minimum quantity, while in other cases the above-mentioned upper limit must be exceeded. In the case of application of larger quantities, it may be advisable to distribute them in several single doses over the day.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002361816A CA2361816A1 (en) | 1999-02-04 | 2000-01-24 | Substituted pyrazole carboxylic acids used to combat anaemias |
JP2000597278A JP2002536365A (ja) | 1999-02-04 | 2000-01-24 | 貧血と闘うのに使用される置換ピラゾールカルボン酸 |
AU32766/00A AU3276600A (en) | 1999-02-04 | 2000-01-24 | Substituted pyrazole carboxylic acids used to combat anaemias |
EP00910605A EP1150958A1 (de) | 1999-02-04 | 2000-01-24 | Substituierte pyrazolcarbonsauren zur bekämpfung von anämien |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19904406A DE19904406A1 (de) | 1999-02-04 | 1999-02-04 | Substituierte Pyrazolcarbonsäuren |
DE19904406.6 | 1999-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000046208A1 true WO2000046208A1 (de) | 2000-08-10 |
Family
ID=7896345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/000511 WO2000046208A1 (de) | 1999-02-04 | 2000-01-24 | Substituierte pyrazolcarbonsäuren zur bekämpfung von anämien |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1150958A1 (de) |
JP (1) | JP2002536365A (de) |
AU (1) | AU3276600A (de) |
CA (1) | CA2361816A1 (de) |
DE (1) | DE19904406A1 (de) |
GT (1) | GT200000007A (de) |
WO (1) | WO2000046208A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006044456A1 (en) * | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
TWI477496B (zh) * | 2009-04-03 | 2015-03-21 | Bayer Cropscience Ag | 製備經吡啶基取代之吡唑類之方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19904397A1 (de) * | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von Pyrazol-Carbonsäureamiden |
EP1932833B1 (de) * | 2005-10-07 | 2012-08-01 | Kissei Pharmaceutical Co., Ltd. | Nitrogenierte heterocyclische verbindung und pharmazeutische zusammensetzung, die diese enthält |
BR122018001851B1 (pt) | 2007-08-13 | 2019-08-20 | Monsanto Technology Llc | Método de controle de nematódeos parasitas de plantas |
JP5466507B2 (ja) | 2007-09-27 | 2014-04-09 | 興和株式会社 | テトラヒドロキノリン化合物を有効成分とする貧血の予防及び/又は治療剤 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5071834A (en) * | 1988-09-16 | 1991-12-10 | Genentech, Inc. | Purified activin B composition |
WO1993025205A1 (en) * | 1992-06-10 | 1993-12-23 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compounds for the treatment of anemia |
WO1996040749A1 (en) * | 1995-06-07 | 1996-12-19 | Johnson & Johnson Corporation | Compounds and peptides that bind to the erythropoietin receptor |
WO1997019039A1 (en) * | 1995-11-17 | 1997-05-29 | Novartis Ag | Solid phase synthesis of heterocyclic compounds and combinatorial compound library |
-
1999
- 1999-02-04 DE DE19904406A patent/DE19904406A1/de not_active Withdrawn
-
2000
- 2000-01-24 WO PCT/EP2000/000511 patent/WO2000046208A1/de not_active Application Discontinuation
- 2000-01-24 AU AU32766/00A patent/AU3276600A/en not_active Abandoned
- 2000-01-24 EP EP00910605A patent/EP1150958A1/de not_active Withdrawn
- 2000-01-24 CA CA002361816A patent/CA2361816A1/en not_active Abandoned
- 2000-01-24 JP JP2000597278A patent/JP2002536365A/ja active Pending
- 2000-02-03 GT GT200000007A patent/GT200000007A/es unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5071834A (en) * | 1988-09-16 | 1991-12-10 | Genentech, Inc. | Purified activin B composition |
WO1993025205A1 (en) * | 1992-06-10 | 1993-12-23 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compounds for the treatment of anemia |
WO1996040749A1 (en) * | 1995-06-07 | 1996-12-19 | Johnson & Johnson Corporation | Compounds and peptides that bind to the erythropoietin receptor |
WO1997019039A1 (en) * | 1995-11-17 | 1997-05-29 | Novartis Ag | Solid phase synthesis of heterocyclic compounds and combinatorial compound library |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006044456A1 (en) * | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
US9611230B2 (en) | 2004-10-13 | 2017-04-04 | Ptc Therapeutics, Inc. | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
TWI477496B (zh) * | 2009-04-03 | 2015-03-21 | Bayer Cropscience Ag | 製備經吡啶基取代之吡唑類之方法 |
Also Published As
Publication number | Publication date |
---|---|
GT200000007A (es) | 2001-07-27 |
EP1150958A1 (de) | 2001-11-07 |
AU3276600A (en) | 2000-08-25 |
JP2002536365A (ja) | 2002-10-29 |
CA2361816A1 (en) | 2000-08-10 |
DE19904406A1 (de) | 2000-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000045799A2 (de) | Verwendung von substituierten isoxazolcarbonsäuren und derivaten und neue stoffe | |
EP0088274B1 (de) | Neue 1,4-Dihydropyridine, Verfahren zu ihrer Herstellung und ihrer Verwendung in Arzneimitteln | |
WO2000058302A1 (de) | Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b | |
DE4430639A1 (de) | Verwendung von 5-substituierten Pyridin- und Hexahydrochinolin-3-carbonsäurederivaten | |
EP0363793A1 (de) | Arylalkoxycumarine, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel | |
EP1345902A1 (de) | Substituierte heterocyclo-norbornylamino-derivate, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament | |
EP0415065B1 (de) | Chromanderivate | |
EP0161599A2 (de) | Neue Benzazepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung | |
DE3630903A1 (de) | Neue tetrahydronaphthalin- und indanderivate, verfahren zu deren herstellung sowie diese enthaltende arzneimittel | |
EP0515940B1 (de) | Neue 2-Amino-5-cyano-1,4-dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln | |
WO2000046208A1 (de) | Substituierte pyrazolcarbonsäuren zur bekämpfung von anämien | |
DE4313693A1 (de) | 2-Amino-4-chinolin-dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung | |
EP0539806B1 (de) | Thiadiazinone und sie enthaltende Arzneimittel, insbesondere mit Positiv-Inotroper und vasodilatierender Wirksamkeit | |
WO2004113325A1 (de) | Indol-derivate als serotonin-wiederaufnahme-inhibitoren | |
EP0351720B1 (de) | Verwendung substituierter 3,4-Dihydro-2H-benzopyrane als Heilmittel gegen obstruktive Funktionsstörungen der Lunge | |
EP1148879A2 (de) | Verwendung von pyrazol-carbonsäureamiden | |
DE3423429A1 (de) | Substituierte phenoxyalkylaminopropanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen | |
EP0778274A1 (de) | Amidinohydrazone vom Benzo(b)furan abgeleiteter Ketone, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
WO2000046206A1 (de) | Substituierte pyrazolbenzylamin-derivate zur bekämpfung von anämien | |
WO2000046207A1 (de) | Pyrazol-alkylamide | |
EP0045911A1 (de) | Neue Aminopropanol-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
DE3640829A1 (de) | Neue 1-aryloxy-3-amino-2-propanole, ihre herstellung und verwendung | |
DE2062055A1 (de) | Propanolamin Derivate | |
EP0721950A2 (de) | Kardioaktive 3-Alkoxycarbonyl-thiadiazinone | |
EP0575361B1 (de) | Neue 1-aryl-4-piperazinyl-cyclohexancarbonsäurenitrile, ihre herstellung und verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000910605 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 597278 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2361816 Country of ref document: CA Ref country code: CA Ref document number: 2361816 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000910605 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09890614 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000910605 Country of ref document: EP |